Antibody Fc Biology in Disease and Therapy

Guest Editor:

Dr. Chang Han Lee
1. Department of Pharmacology, Seoul National University College of Medicine, Seoul, Republic of Korea
2. Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea
3. Convergence Research Center for Dementia, Seoul National University Medical Research Center, Seoul, Republic of Korea
4. Wide River Institute of Immunology, Seoul National University, Hongcheon, Republic of Korea

Deadline for manuscript submissions:
closed (31 December 2021)

Message from the Guest Editor

Dear Colleagues,

Antibodies are one of the most successful biomolecules as therapeutic agents, but we still do not know exactly what immune responses antibodies induce in adaptive and innate immunities. The antibody IgG, for example, binds to a several Fc receptors (six FcγRs, complement C1q, FcRL5, FcRn, TRIM21, and type II lectin receptors). The interaction between antigen-bound antibodies (immune complexes, ICs) and Fc receptors is capable of eliciting a variety of known and unknown immune responses. Thus, in order to maximize the therapeutic efficacy of antibodies, a better understanding of Fc receptors is essential. In addition, the engineered antibodies that have modulated the binding ability to Fc receptors have begun to be used and show enhanced efficacies.

Collectively, a better understanding of antibody functions in disease and therapy will provide the basis for developing new concepts of therapeutic antibodies.

This Research Topic will focus on (i) the diverse immunological functions of the Fc receptors and (ii) new engineered antibodies based on Fc biology.

Prof. Chang Han Lee
Guest Editor

Special Issue

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us